iBio
IBIO
57 hedge funds and large institutions have $22.6M invested in iBio in 2020 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 9 closing their positions.
597% more capital invested
Capital invested by funds: $3.24M → $22.6M (+$19.4M)
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
104% more funds holding
Funds holding: 28 → 57 (+29)
0.01% more ownership
Funds ownership: 0.01% → 0.02% (+0.01%)
Top Buyers
| 1 |
BlackRock
New York
|
+$4.58M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$994K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$828K |
| 4 |
State Street
Boston,
Massachusetts
|
+$646K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$494K |
Top Sellers
IBIO Hedge Fund Activity: Q2 2020 in Review
57 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2020, worth a combined $22.6M — up 597% from $3.24M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IBIO positions and 9 closed out — a net gain of 29 holders — while 11 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $4.58M. The largest seller was Thrivent Financial for Lutherans, exiting entirely with an estimated $337K sold.
- 57 institutional investors held iBio (IBIO) as of Q2 2020, up from 28 in Q1 2020.
- Funds reported $22.6M of iBio stock for Q2 2020, up 597% quarter-over-quarter.
- 38 funds opened new iBio positions in Q2 2020 and 9 closed out, a net change of +29 holders.
- The largest iBio buyer in Q2 2020 was BlackRock, an estimated $4.58M added.
- The largest iBio seller in Q2 2020 was Thrivent Financial for Lutherans, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2020.